Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response

Journal of Immunotherapy

Volumn 24, Issue 3, 2001, Pages 193-194

  Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA ANTIGEN; TUMOR ANTIGEN; VIRUS LARGE T ANTIGEN;

CANCER IMMUNOTHERAPY; COMPUTER PROGRAM; HUMAN; IMMUNOLOGICAL TOLERANCE; MELANOMA; NONHUMAN; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, POLYOMAVIRUS TRANSFORMING; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; MALE; MELANOMA; MICE; NEOPLASMS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 0035020884     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200105000-00001     Document Type: Editorial

References (16)

1. Chen W, Anton LC, Bennink JR, et al. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000;12:83-93. 12:83-93.
2. Kedl RM, Rees WA, Hildeman DA, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000; 192:1105-13.
3. Grossmann ME, Davila E, Celis E. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 2001; 24:237-241.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-9.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
6. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188:277-86.
7. Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000; 191:1221-32.
8. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999; 96:2982-7.
9. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92:3439-43.
10. Mylin LM, Bonneau RH, Lippolis JD, et al. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 1995; 69:6665-77.
11. Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res 2000; 60:3002-12.
12. Newmaster RS, Mylin LM, Fu TM, et al. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Virology 1998; 244:427-41.
13. Cibotti R, Kanellopoulos JM, Cabaniols JP, et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 1992; 89:416-20.
14. Benichou G, Fedoseyeva E, Olson CA, et al. Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant. Int Immunol 1994; 6:131-8.
15. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000; 12:597-603.
16. Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999; 11:50-7.